Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer.
Hitomi YamashitaKentaro NakayamaKosuke KannoTomoka IshibashiMasako IshikawaKouji IidaSultana RaziaTohru KiyonoSatoru KyoPublished in: Cancers (2024)
ARID1A negativity is not suitable as a biomarker for ICI effectiveness in treating endometrial cancer.